Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2025-06-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
董事会关于本次交易不构成《上市公司重大资产重组管理办法》第十三条规定的重组上市情形的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors of a company regarding a transaction involving the sale of certain business units. It explicitly states that the transaction does not constitute a major asset restructuring under relevant regulatory rules. The document is short (375 characters) and serves as an announcement or explanation rather than a detailed report or financial statement. It does not contain financial data or detailed analysis, nor is it a regulatory certification or voting result. The content fits best under a Regulatory Filing (RNS) as a general regulatory announcement explaining the nature of the transaction and compliance with listing rules.
2025-06-27 Chinese
浙商证券股份有限公司作为绿康生化股份有限公司独立财务顾问在充分尽职调查和内核基础上出具的承诺函
Regulatory Filings Classification · 95% confidence The document is a commitment letter issued by an independent financial advisor (浙商证券股份有限公司) regarding a major asset restructuring transaction involving the sale of subsidiaries by 绿康生化股份有限公司. It references regulatory guidelines related to major asset restructurings and confirms due diligence and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial data but is a formal attestation and advisory opinion related to a transaction. This fits the category of a Regulatory Filing (RNS) as it is a compliance and advisory document rather than a full report or announcement of financial results or capital changes.
2025-06-27 Chinese
董事会关于公司本次重大资产重组前12个月内购买、出售资产情况的说明
Capital/Financing Update Classification · 95% confidence The document is a statement from the board of directors of 绿康生化股份有限公司 regarding asset transactions within the 12 months prior to a major asset restructuring. It details specific asset sales and clarifies that these transactions do not need to be cumulatively calculated for the current major asset restructuring. The content focuses on asset sales and compliance with regulatory requirements related to major asset restructuring disclosures. It is not a full report but an explanatory statement about asset transactions related to a major asset restructuring. This fits the category of Capital/Financing Update (CAP), as it provides updates on significant asset sales and restructuring activities affecting the company's capital structure.
2025-06-27 Chinese
董事会关于关于本次交易采取的保密措施及保密制度的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors of 绿康生化股份有限公司 regarding the confidentiality measures and confidentiality system adopted for a major asset sale and related party transaction. It references compliance with Chinese securities laws and regulations, mentions engagement of independent financial advisors, legal counsel, auditors, and appraisal agencies, and details internal confidentiality controls. The document is a disclosure about the confidentiality procedures during a transaction process, not a financial report, earnings release, or regulatory filing of financial results. It is not an announcement of voting results, management changes, or capital changes. It is a regulatory announcement related to transaction confidentiality and compliance with disclosure rules. Given the content and length (676 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-06-27 Chinese
绿康生化股份有限公司审阅报告
Audit Report / Information Classification · 95% confidence The document is a detailed financial report including an auditor's review report and pro forma (备考) consolidated financial statements for the years 2023 and 2024. It contains comprehensive financial data such as balance sheets, income statements, notes to the financial statements, accounting policies, and explanations related to a major asset restructuring. The document references Chinese regulatory standards and is prepared for submission to regulatory authorities in connection with a major asset restructuring transaction. The length is substantial (15,000 characters), and it contains actual financial statements and detailed notes, not just an announcement or certification. This matches the definition of an Audit Report / Information (AR), which includes standalone audit or review reports and related financial statements excluding full annual reports. It is not a full Annual Report (10-K) because it is specifically a review report and pro forma financials for a restructuring purpose, not a comprehensive yearly report covering all company activities. Therefore, the correct classification is AR with high confidence. FY 2024
2025-06-27 Chinese
浙商证券股份有限公司关于本次交易摊薄即期回报情况及填补措施的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding the dilution of immediate returns from a specific transaction involving the sale of subsidiaries by a listed company. It includes financial data analysis, commitments from company directors and controlling shareholders, and compliance with regulatory guidelines from Chinese securities authorities. The document is not a full annual or interim report, nor is it a simple announcement or certification. It is a standalone audit-related opinion focusing on the financial impact of a transaction and related compliance measures, fitting the definition of an Audit Report / Information (AR). The document length is under 5,000 characters but contains substantive financial data and detailed analysis, so it is not a mere announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-06-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.